Advertisement

Pharmaceutisch Weekblad

, Volume 12, Issue 6, pp 262–267 | Cite as

Pharmacokinetics and tissue concentrations of cefuroxime

  • T. B. Vree
  • Y. A. Hekster
Antibiotics in Gynaecology and Obstetrics

Abstract

Cefuroxime is well-absorbed and distributed over the human body. This review gives a general summary of published information on tissue concentrations of cefuroxime after an intravenous or intramuscular dose of 750 or 1,500 mg of cefuroxime. Tissue concentrations are given for blister fluid, meninges, eyes, respiratory tract, sputum and bronchi, abdominal and urogenital tract, uterine, ovarian and fallopian tube tissue, myometrium, membranes, placenta, puruloid and healthy human milk, bile, prostate, hip and knee bone. Pharmacokinetics are reviewed in patients with impaired kidney function and in pregnancy.

Keywords

Body fluids Cefuroxime Pharmacokinetics Tissue distribution 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Eykyn S, Jenkins C, King A, Phillips I. Antibacterial activity of cefuroxime, a new cephalosporin, compared with that of cephaloridine, cephalothin and cefamandole. Antimicrob Agents Chemother 1976;9:690–5.PubMedGoogle Scholar
  2. 2.
    Neu HC, Fu KP. Cefuroxime, a beta-lactamase resistant cephalosporin with a broad spectrum of Grampositive and -negative activity. Antimicrob Agent Chemother 1978;13:657–64.Google Scholar
  3. 3.
    Norrby SR. Role of cephalosporins in the treatment of bacterial meningitis in adults. Am J Med 1985;79 (Suppl 2A):56–61.CrossRefGoogle Scholar
  4. 4.
    Verbist L, Vanderheyden JS. Penetration of cefuroxime into human uterine and ovarian tissue. Res Clin Forums 1984;6:13–7.Google Scholar
  5. 5.
    Ginsburg CM, McCracken GH, Petruska M, Olson K. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 1985;28:504–7.PubMedGoogle Scholar
  6. 6.
    McCracken GH, Nelson JD, Grimm L. Pharmacokinetics and bacteriological efficacy of cefoperazone, cefuroxime, ceftriaxone and moxalactam in experimentalStreptococcus pneumoniae andHaemophilus influenzae meningitis. Antimicrob Agents Chemother 1982;21:262–7.PubMedGoogle Scholar
  7. 7.
    Sommers DK, Van Wijk M, Williams POE, Harding SM. Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob Agents Chemother 1984;25:344–7.PubMedGoogle Scholar
  8. 8.
    Wise R, Bennett SA, Dent J. The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J Antimicrob Chemother 1984;13:603–10.PubMedGoogle Scholar
  9. 9.
    Van Dalen R, Vree TB, Baars AM. Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients. Pharm Weekbl [Sci] 1987;9:98–103.Google Scholar
  10. 10.
    Foord RD. Cefuroxime. Human pharmacokinetics. Antimicrob Agents Chemother 1976;9:741–7.PubMedGoogle Scholar
  11. 11.
    Williams PEO, Harding SM. The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food. J Antimicrob Chemother 1984;13:191–6.PubMedGoogle Scholar
  12. 12.
    Gillet AB, Wise R. Penetration of four cephalosporins into tissue fluid in man. Lancet 1978;1:962–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Simon C, Malerczyk V. Serum and skin blister concentrations of cefuroxime in relation to dose in comparison to cephalotin. Proc R Soc Med 1977;70(Suppl 9):19–21.Google Scholar
  14. 14.
    Leabeater B, Kingston J. Cefuroxime and metronidazole in gynaecological surgery. Br J Obstet Gynaecol 1981;88:543–7.PubMedGoogle Scholar
  15. 15.
    Pritchard JM, Elder MG, Kennedy MRK. Pelvic tissue levels of cefuroxime. J Infect 1981;3:193–4.PubMedGoogle Scholar
  16. 16.
    O'Callaghan CH, Harding SM. The pharmacokinetics of cefuroxime in man in relation to its antibacterial activity. Proc R Soc Med 1977;70(Suppl 9):4–10.Google Scholar
  17. 17.
    Craft I, Mullinger BM, Kennedy MR. Placental transfer of cefuroxime. In: Nelson JD, Grassi GG, eds. Current chemotherapy and infectious dissease. Washington: American Society for Microbiology, 1980:1144–5.Google Scholar
  18. 18.
    Bergogne-Berezin E, Pierre J, Rouvillois JL. Placental transfer of cefuroxime. In: Nelson JD, Grassi GG, eds. Current chemotherapy and infectious dissease. Washington: American Society for Microbiology, 1980:1168–9.Google Scholar
  19. 19.
    Brogard JM, Pinget M, Arnaud JP. Biliary excretion of cefuroxime. Chemotherapy 1981;27:18–28.PubMedGoogle Scholar
  20. 20.
    Mullinger BM, House CA. Penetration of cefuroxime and other parenteral cephalosporins into various tissues and body fluids. In: Wood C, Rue Y, eds. Cefuroxime update. London: Royal Society of Medicine/Academic Press 1981;141–151. (International congress and symposium series; No. 38.)Google Scholar
  21. 21.
    Adam D, Schalkhäuser K, Boettger F. Zur Diffusion von Cefuroxim in das Prostata und andere Gewebe des Urogenitalbereichs. Med Klin 1979;74:1867–70.PubMedGoogle Scholar
  22. 22.
    Philipson A, Stiernstedt G. Pharmacokinetics of cefuroxime in pregnancy. Am J Obstet Gynecol 1982;142:823–8.PubMedGoogle Scholar
  23. 23.
    Bousfield P, Browning AK, Mullinger BM, Elstein M. Cefuroxime: potential use in pregnant woman at term. Br J Obstet Gynaecol 1981;88:146–9.PubMedGoogle Scholar
  24. 24.
    Nakamura T, Hashimoto I, Sawada Y, Mikami J. Clinical studies on cefuroxime axetil in acute mastitis. Jpn J Antibiot 1987;60:340–8.Google Scholar
  25. 25.
    Akhtamova ZM, Kholodov IE, Dorokhov VV, Voropaeva SD. Pharmacokinetics of cefuroxime in pregnant woman with acute pyelonephritis. Antibiot Med Biothekhnol 1985;30:124–8.Google Scholar
  26. 26.
    Van Dalen R, Vree TB, Hafkenscheid JCM, Gimbrère JSF. Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency. J Antimicrob Chemother 1979;5:281–92.PubMedGoogle Scholar
  27. 27.
    Walstad RA, Nilsen OG, Berg KJ. Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency. Eur J Clin Pharmacol 1983;24:391–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Chan MK, Browning AK, Poole CJM, Matheson LA, et al. Cefuroxime pharmacokinetics in continuous and intermittent peritoneal dialysis. Nephron 1985;41:161–5.PubMedGoogle Scholar
  29. 29.
    Bonati M, Kanto J, Tognoni G. Clinical pharmacokinetics of cerebrospinal fluid. Clin Pharmacokinet 1982;7:312–35.PubMedGoogle Scholar
  30. 30.
    Netland A, Muller C, Andrew E. Concentration of cefuroxime in cerebrospinal fluid in patients with bacterial meningitis. Scand J Infect Dis 1981;13:273–5.PubMedGoogle Scholar
  31. 31.
    Schaad UB, Krucko J, Pfenninger J. An extended experience with cefuroxime therapy of childhood bacterial meningitis. Pediatr Infect Dis J 1984;3:410–6.Google Scholar
  32. 32.
    Pfenninger J, Schaad UB, Lutschg J, Nussbaumer A, Zellweger U. Cefuroxime in bacterial meningitis. Arch Dis Child 1982;57:539–43.PubMedGoogle Scholar
  33. 33.
    Müller C, Netland A, Dawson AF, Andrew E. The penetration of cefuroxime into the cerebrospinal fluid through inflamed and non-inflamed meningis. J Antimicrob Chemother 1980;6:279–83.PubMedGoogle Scholar
  34. 34.
    Smith BR, LeFrock JL. Cefuroxime: antimicrobial activity, pharmacology, and clinical efficacy. Ther Drug Monitor 1983;5:149–60.Google Scholar
  35. 35.
    Edwards MS, Baker CJ, Butler KM, Mason EO, Laurent JP, Cheek WR. Penetration of cefuroxime into ventricular fluid in cerebrospinal fluid shunt infections. Antimicrob Agents Chemother 1989;33:1108–10.PubMedGoogle Scholar
  36. 36.
    Perea EJ, Ayarra J, Garcia Iglesias MC, Garcia Luque I, Loscertales J. Penetration of cefuroxime and ceftazidime into human lungs. Chemotherapy 1988;34:1–7.Google Scholar
  37. 37.
    Bergogne-Berezin E. Penetration of antibiotics into the respiratory tree. J Antibiot Chemother 1981;8:171–4.Google Scholar
  38. 38.
    Havard CHW, Bax RP, Samanta TC, et al. Sputum and blood concentrations of cefuroxime in lower respiratory tract infection. Thorax 1980;35:379–83.PubMedGoogle Scholar
  39. 39.
    Havard CWH, Fernando A, Bannister B, Brumfitt W, Hamilton-Miller JMT. Clinical and pharmacokinetic comparison of cefuroxime sodium and cefuroxime lysine in the treatment of lower respiratory tract infections. J Antimicrob Chemother 1981;8:401–8.PubMedGoogle Scholar
  40. 40.
    Daikos GK, Kosmidis J, Stathakis C. Bioavailability of cefuroxime in various sites including bile, sputum and bone. Proc R Soc Med 1977;70(Suppl 9):38–41.Google Scholar
  41. 41.
    Hajiroussou V, Joshi R, Bullas J. Cefuroxime in the treatment of lower respiratory tract infections. In: Woods C, Rue Y, eds. Cefuroxime update. London: Royal Society of Medicine/Academic Press, 1981:123–33. (International congress and symposium series; No. 38.)Google Scholar
  42. 42.
    Leigh DA. Serum and bone concentrations of cefuroxime in patients undergoing knee arthroplasty. J Antimicrob Chemother 1986;18:609–11.PubMedGoogle Scholar
  43. 43.
    Leigh DA, Marriner J, Nisbet D, Powell HDW, Church JCT, Wise K. Bone concentrations of cefuroxime and cefamandole in the femoral head in 96 patients undergoing total hip replacement surgery. J Antimicrob Chemother 1982;9:303–11.PubMedGoogle Scholar
  44. 44.
    Hedström SA, Lidgren L, Nilsson-Ehle I. Cefuroxime in acute septic arthritis. Scand J Infect Dis 1984;16:79–82.PubMedGoogle Scholar
  45. 45.
    Andreasen JJ, Möller S, Hauch O, et al. Peroperative concentrations of cefuroxime in serum and subcutaneous tissue following antimicrobial prophylaxis in gastrointestinal surgery. J Antimicrob Chemother 1988;67:90–2.Google Scholar
  46. 46.
    Bullen BR, Ramsden CH, Kester RC. Cefuroxime levels attained in tissues and wound exudates from severely ischemic limbs. J Antimicrob Chemother 1981;7:163–9.PubMedGoogle Scholar
  47. 47.
    Richards AB, Bron AJ, McLendon B. The intraocular penetration of cefuroxime after parenteral administration. Br J Ophthamol 1979;63:687–9.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1990

Authors and Affiliations

  • T. B. Vree
    • 1
  • Y. A. Hekster
    • 1
  1. 1.Department of Clinical PharmacyUniversity HospitalHB Nijmegenthe Netherlands

Personalised recommendations